Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
United Therapeutics Corp Market Cap
From what 13 stock analysts predict, the share price for United Therapeutics Corp (UTHR) might increase by 3.26% in the next year. This is based on a 12-month average estimation for UTHR. Price targets go from $243 to $575. The majority of stock analysts believe UTHR is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assignedUTHR 2 buy ratings, 6 hold ratings, and 5 sell ratings. This means that analysts expect United Therapeutics Corp to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on UTHR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of UTHR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Eun Yang Jefferies | Buy | $432 | Maintains | Sep 23, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $575 | Maintains | Aug 28, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $380 | Maintains | Aug 20, 2024 |
| Greg Harrison B of A Securities | Underperform | $280 | Maintains | Aug 1, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $400 | Reiterates | Aug 1, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $400 | Maintains | Jul 25, 2024 |
| Joseph Thome TD Cowen | Buy | $350 | Maintains | Jul 11, 2024 |
| Terence Flynn Morgan Stanley | Equal-Weight | $321 | Downgrade | Jul 11, 2024 |
| Ashwani Verma UBS | Buy | $370 | Maintains | Jul 8, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $350 | Maintains | Jun 12, 2024 |
| Jessica Fye JP Morgan | Overweight | $300 | Maintains | May 21, 2024 |
| Chris Shibutani Goldman Sachs | Neutral | $240 | Maintains | May 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $300 | Reiterates | May 2, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $400 | Maintains | May 2, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $325 | Maintains | Mar 7, 2024 |
| Liana Moussatos Wedbush | Outperform | $308 | Reiterates | Feb 22, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $300 | Reiterates | Feb 22, 2024 |
| Chris Shibutani Goldman Sachs | Neutral | $215 | Upgrade | Feb 12, 2024 |
| Roanna Ruiz Leerink Partners | Outperform | $330 | Initiates | Feb 5, 2024 |
| Terence Flynn Morgan Stanley | Overweight | $314 | Maintains | Nov 2, 2023 |
When did it IPO
1999
Staff Count
1,168
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Market Cap
$15.84B
In 2023, UTHR generated $2.33B in revenue, which was a increase of 20.20% from the previous year. This can be seen as a signal that UTHR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - United Therapeutics (Nasdaq: UTHR) will present five presentations and one poster at the CHEST 2024 Annual Meeting from October 6-9, 2024, in Boston, focusing on its Tyvaso DPI® product.
Why It Matters - United Therapeutics' presentations at a major medical conference highlight its product visibility and innovation, potentially influencing stock performance and investor sentiment.
Fri, 20 Sep 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - The top five biotech stocks currently share strong ratings, indicating positive performance and investor confidence in the sector.
Why It Matters - Strong ratings for the top biotech stocks suggest robust investor confidence, potential for growth, and market stability, influencing stock performance and investment decisions.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - United Therapeutics Corporation (Nasdaq: UTHR) released its 2024 Corporate Responsibility and Public Benefit Report, detailing FY 2023 progress on public benefit goals and financial performance.
Why It Matters - United Therapeutics' 2024 report highlights financial performance and commitment to public benefit, signaling potential growth and increased stakeholder value, which can influence stock performance.
Fri, 30 Aug 2024
Sentiment - POSITIVE
Source - FXEmpire
Summary - United Therapeutics Corporation (UTHR) shares are rising due to revenue growth and a recent favorable regulatory outcome.
Why It Matters - Revenue growth signals strong operational performance, while a regulatory win can enhance market position, both likely boosting UTHR's stock attractiveness and future profitability.
Fri, 30 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - United Therapeutics (UTHR) reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for potential stock movement.
Why It Matters - Earnings reports can influence stock performance. Analysts will assess UTHR's financial health and future outlook, impacting investor sentiment and stock price movements.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - United Therapeutics Corporation (Nasdaq: UTHR) will present updates on its operations at the Morgan Stanley Global Healthcare Conference on September 4, 2024, in New York City.
Why It Matters - United Therapeutics' participation in major investor conferences signals transparency and potential strategic developments, which can influence investor confidence and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
